{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:51:15Z","timestamp":1793890275588,"version":"4.8.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"8015","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2024,6,6]]},"DOI":"10.1038\/s41586-024-07410-3","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T16:02:58Z","timestamp":1715184178000},"page":"198-205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Targetable leukaemia dependency on noncanonical PI3K\u03b3 signalling"],"prefix":"10.1038","volume":"630","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-637X","authenticated-orcid":false,"given":"Qingyu","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline G.","family":"Raulston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4914-1619","authenticated-orcid":false,"given":"Miguel A.","family":"Prado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4176-7198","authenticated-orcid":false,"given":"Xiaowei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Gritsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karley S.","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kezhi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3841-6637","authenticated-orcid":false,"given":"Christopher A. G.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5023-3281","authenticated-orcid":false,"given":"Ran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0735-1570","authenticated-orcid":false,"given":"Peter","family":"van Galen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3707-9889","authenticated-orcid":false,"given":"John G.","family":"Doench","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-9652","authenticated-orcid":false,"given":"Shai","family":"Shimony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6849-6629","authenticated-orcid":false,"given":"Henry W.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2566-3145","authenticated-orcid":false,"given":"Donna S.","family":"Neuberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4291-413X","authenticated-orcid":false,"given":"Joao A.","family":"Paulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7380-0226","authenticated-orcid":false,"given":"Andrew A.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"key":"7410_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20554","volume":"539","author":"O De Henau","year":"2016","unstructured":"De Henau, O. et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells. Nature 539, 443\u2013447 (2016).","journal-title":"Nature"},{"key":"7410_CR2","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1158\/2159-8290.CD-15-1346","volume":"6","author":"MM Kaneda","year":"2016","unstructured":"Kaneda, M. M. et al. Macrophage PI3K\u03b3 drives pancreatic ductal adenocarcinoma progression. Cancer Discov. 6, 870\u2013885 (2016).","journal-title":"Cancer Discov."},{"key":"7410_CR3","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1158\/2159-8290.CD-16-0716","volume":"6","author":"K Okkenhaug","year":"2016","unstructured":"Okkenhaug, K., Graupera, M. & Vanhaesebroeck, B. Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. Cancer Discov. 6, 1090\u20131105 (2016).","journal-title":"Cancer Discov."},{"key":"7410_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature19834","volume":"539","author":"MM Kaneda","year":"2016","unstructured":"Kaneda, M. M. et al. PI3K\u03b3 is a molecular switch that controls immune suppression. Nature 539, 437\u2013442 (2016).","journal-title":"Nature"},{"key":"7410_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41580-019-0129-z","volume":"20","author":"B Bilanges","year":"2019","unstructured":"Bilanges, B., Posor, Y. & Vanhaesebroeck, B. PI3K isoforms in cell signalling and vesicle trafficking. Nat. Rev. Mol. Cell Biol. 20, 515\u2013534 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"7410_CR6","doi-asserted-by":"publisher","unstructured":"Chi, S. G. & Minami, Y. Emerging targeted therapy for specific genomic abnormalities in acute myeloid leukemia. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms23042362 (2022).","DOI":"10.3390\/ijms23042362"},{"key":"7410_CR7","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bjh.17746","volume":"196","author":"S Kayser","year":"2022","unstructured":"Kayser, S. & Levis, M. J. Updates on targeted therapies for acute myeloid leukaemia. Br. J. Haematol. 196, 316\u2013328 (2022).","journal-title":"Br. J. Haematol."},{"key":"7410_CR8","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1182\/blood.V97.10.3210","volume":"97","author":"L Chaperot","year":"2001","unstructured":"Chaperot, L. et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 97, 3210\u20133217 (2001).","journal-title":"Blood"},{"key":"7410_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/bjh.14146","volume":"174","author":"L Pagano","year":"2016","unstructured":"Pagano, L., Valentini, C. G., Grammatico, S. & Pulsoni, A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br. J. Haematol. 174, 188\u2013202 (2016).","journal-title":"Br. J. Haematol."},{"key":"7410_CR10","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/S2152-2650(20)30466-3","volume":"20","author":"AA Lane","year":"2020","unstructured":"Lane, A. A. Targeting CD123 in AML. Clin. Lymphoma Myeloma Leuk. 20, S67\u2013S68 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"7410_CR11","doi-asserted-by":"publisher","unstructured":"Luskin, M. R. & Lane, A. A. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm. Haematologica https:\/\/doi.org\/10.3324\/haematol.2022.282171 (2023).","DOI":"10.3324\/haematol.2022.282171"},{"key":"7410_CR12","first-page":"cm2","volume":"2007","author":"S Andrews","year":"2007","unstructured":"Andrews, S., Stephens, L. R. & Hawkins, P. T. PI3K class IB pathway. Sci. STKE 2007, cm2 (2007).","journal-title":"Sci. STKE"},{"key":"7410_CR13","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1038\/onc.2008.245","volume":"27","author":"TL Yuan","year":"2008","unstructured":"Yuan, T. L. & Cantley, L. C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497\u20135510 (2008).","journal-title":"Oncogene"},{"key":"7410_CR14","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","volume":"28","author":"KD Courtney","year":"2010","unstructured":"Courtney, K. D., Corcoran, R. B. & Engelman, J. A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28, 1075\u20131083 (2010).","journal-title":"J. Clin. Oncol."},{"key":"7410_CR15","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-20-1513","volume":"12","author":"K Togami","year":"2022","unstructured":"Togami, K. et al. Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis. Cancer Discov. 12, 522\u2013541 (2022).","journal-title":"Cancer Discov."},{"key":"7410_CR16","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.ccell.2016.03.008","volume":"29","author":"EC Townsend","year":"2016","unstructured":"Townsend, E. C. et al. The public repository of xenografts enables discovery and randomized phase II-like trials in mice. Cancer Cell 29, 574\u2013586 (2016).","journal-title":"Cancer Cell"},{"key":"7410_CR17","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1038\/s41596-020-0379-4","volume":"15","author":"E Driehuis","year":"2020","unstructured":"Driehuis, E., Kretzschmar, K. & Clevers, H. Establishment of patient-derived cancer organoids for drug-screening applications. Nat. Protoc. 15, 3380\u20133409 (2020).","journal-title":"Nat. Protoc."},{"key":"7410_CR18","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","unstructured":"Cancer Genome Atlas Research Networket al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059\u20132074 (2013).","journal-title":"N. Engl. J. Med."},{"key":"7410_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"7410_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0301-472X(03)00066-3","volume":"31","author":"A Cignetti","year":"2003","unstructured":"Cignetti, A. et al. The characterization of chemokine production and chemokine receptor expression reveals possible functional cross-talks in AML blasts with monocytic differentiation. Exp. Hematol. 31, 495\u2013503 (2003).","journal-title":"Exp. Hematol."},{"key":"7410_CR21","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1182\/blood.V74.6.2081.2081","volume":"74","author":"CE van der Schoot","year":"1989","unstructured":"van der Schoot, C. E. et al. Interleukin-6 and interleukin-1 production in acute leukemia with monocytoid differentiation. Blood 74, 2081\u20132087 (1989).","journal-title":"Blood"},{"key":"7410_CR22","doi-asserted-by":"publisher","first-page":"965018","DOI":"10.3389\/fimmu.2022.965018","volume":"13","author":"Y Du","year":"2022","unstructured":"Du, Y. et al. Toll-like receptor-mediated innate immunity orchestrates adaptive immune responses in HBV infection. Front. Immunol. 13, 965018 (2022).","journal-title":"Front. Immunol."},{"key":"7410_CR23","doi-asserted-by":"publisher","first-page":"812774","DOI":"10.3389\/fimmu.2022.812774","volume":"13","author":"T Duan","year":"2022","unstructured":"Duan, T., Du, Y., Xing, C., Wang, H. Y. & Wang, R. F. Toll-like receptor signaling and its role in cell-mediated immunity. Front. Immunol. 13, 812774 (2022).","journal-title":"Front. Immunol."},{"key":"7410_CR24","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.3324\/haematol.2011.044792","volume":"96","author":"E Arvaniti","year":"2011","unstructured":"Arvaniti, E. et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica 96, 1644\u20131652 (2011).","journal-title":"Haematologica"},{"key":"7410_CR25","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s11684-015-0412-0","volume":"9","author":"J Cannova","year":"2015","unstructured":"Cannova, J., Breslin, S. J. P. & Zhang, J. Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases. Front. Med. 9, 288\u2013303 (2015).","journal-title":"Front. Med."},{"key":"7410_CR26","doi-asserted-by":"publisher","first-page":"D56","DOI":"10.1093\/nar\/gks1172","volume":"41","author":"KR Rosenbloom","year":"2013","unstructured":"Rosenbloom, K. R. et al. ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic Acids Res. 41, D56\u2013D63 (2013).","journal-title":"Nucleic Acids Res."},{"key":"7410_CR27","doi-asserted-by":"publisher","first-page":"18862","DOI":"10.1073\/pnas.1304801110","volume":"110","author":"O Vadas","year":"2013","unstructured":"Vadas, O. et al. Molecular determinants of PI3K\u03b3-mediated activation downstream of G-protein-coupled receptors (GPCRs). Proc. Natl Acad. Sci. USA 110, 18862\u201318867 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"7410_CR28","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","volume":"24","author":"JR Molina","year":"2018","unstructured":"Molina, J. R. et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat. Med. 24, 1036\u20131046 (2018).","journal-title":"Nat. Med."},{"key":"7410_CR29","doi-asserted-by":"publisher","first-page":"151313","DOI":"10.1016\/j.ejcb.2023.151313","volume":"102","author":"K Zaoui","year":"2023","unstructured":"Zaoui, K. & Duhamel, S. RhoB as a tumor suppressor: it\u2019s all about localization. Eur. J. Cell Biol. 102, 151313 (2023).","journal-title":"Eur. J. Cell Biol."},{"key":"7410_CR30","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.1038\/s41388-020-01484-9","volume":"39","author":"X Guan","year":"2020","unstructured":"Guan, X. et al. EZH2 overexpression dampens tumor-suppressive signals via an EGR1 silencer to drive breast tumorigenesis. Oncogene 39, 7127\u20137141 (2020).","journal-title":"Oncogene"},{"key":"7410_CR31","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1038\/s41388-020-01418-5","volume":"39","author":"SH Shin","year":"2020","unstructured":"Shin, S. H., Kim, I., Lee, J. E., Lee, M. & Park, J. W. Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer. Oncogene 39, 5839\u20135854 (2020).","journal-title":"Oncogene"},{"key":"7410_CR32","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s43018-022-00394-x","volume":"3","author":"KH Lin","year":"2022","unstructured":"Lin, K. H. et al. P2RY2\u2013AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. Nat. Cancer 3, 837\u2013851 (2022).","journal-title":"Nat. Cancer"},{"key":"7410_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.semcancer.2018.01.006","volume":"54","author":"CK Rane","year":"2019","unstructured":"Rane, C. K. & Minden, A. p21 Activated kinase signaling in cancer. Semin. Cancer Biol. 54, 40\u201349 (2019).","journal-title":"Semin. Cancer Biol."},{"key":"7410_CR34","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1182\/blood-2014-12-618801","volume":"126","author":"A Pandolfi","year":"2015","unstructured":"Pandolfi, A. et al. PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. Blood 126, 1118\u20131127 (2015).","journal-title":"Blood"},{"key":"7410_CR35","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short, N. J., Rytting, M. E. & Cortes, J. E. Acute myeloid leukaemia. Lancet 392, 593\u2013606 (2018).","journal-title":"Lancet"},{"key":"7410_CR36","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ccell.2018.08.007","volume":"34","author":"AL Boyd","year":"2018","unstructured":"Boyd, A. L. et al. Identification of chemotherapy-induced leukemic-regenerating cells reveals a transient vulnerability of human AML recurrence. Cancer Cell 34, 483\u2013498.e5 (2018).","journal-title":"Cancer Cell"},{"key":"7410_CR37","doi-asserted-by":"publisher","unstructured":"Rathinaswamy, M. K. et al. Structure of the phosphoinositide 3-kinase (PI3K) p110\u03b3\u2013p101 complex reveals molecular mechanism of GPCR activation. Sci. Adv. https:\/\/doi.org\/10.1126\/sciadv.abj4282 (2021).","DOI":"10.1126\/sciadv.abj4282"},{"key":"7410_CR38","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1126\/science.7624799","volume":"269","author":"B Stoyanov","year":"1995","unstructured":"Stoyanov, B. et al. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 269, 690\u2013693 (1995).","journal-title":"Science"},{"key":"7410_CR39","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","volume":"7","author":"T Farge","year":"2017","unstructured":"Farge, T. et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 7, 716\u2013735 (2017).","journal-title":"Cancer Discov."},{"key":"7410_CR40","doi-asserted-by":"publisher","unstructured":"Pei, S. et al. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1297 (2023).","DOI":"10.1158\/2159-8290.CD-22-1297"},{"key":"7410_CR41","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei, S. et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 10, 536\u2013551 (2020).","journal-title":"Cancer Discov."},{"key":"7410_CR42","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3324\/haematol.2018.214882","volume":"105","author":"H Kuusanmaki","year":"2020","unstructured":"Kuusanmaki, H. et al. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica 105, 708\u2013720 (2020).","journal-title":"Haematologica"},{"key":"7410_CR43","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","volume":"1","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat. Cancer 1, 826\u2013839 (2020).","journal-title":"Nat. Cancer"},{"key":"7410_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07901-8","volume":"9","author":"KR Sanson","year":"2018","unstructured":"Sanson, K. R. et al. Optimized libraries for CRISPR\u2013Cas9 genetic screens with multiple modalities. Nat. Commun. 9, 5416 (2018).","journal-title":"Nat. Commun."},{"key":"7410_CR45","doi-asserted-by":"publisher","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","volume":"141","author":"EP Garcia","year":"2017","unstructured":"Garcia, E. P. et al. Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer. Arch. Pathol. Lab. Med. 141, 751\u2013758 (2017).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"7410_CR46","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jmoldx.2016.02.003","volume":"18","author":"MJ Kluk","year":"2016","unstructured":"Kluk, M. J. et al. Validation and implementation of a custom next-generation sequencing clinical assay for hematologic malignancies. J. Mol. Diagn. 18, 507\u2013515 (2016).","journal-title":"J. Mol. Diagn."},{"key":"7410_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15221-z","volume":"11","author":"L Cabal-Hierro","year":"2020","unstructured":"Cabal-Hierro, L. et al. Chromatin accessibility promotes hematopoietic and leukemia stem cell activity. Nat. Commun. 11, 1406 (2020).","journal-title":"Nat. Commun."},{"key":"7410_CR48","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative Genomics Viewer. Nat. Biotechnol. 29, 24\u201326 (2011).","journal-title":"Nat. Biotechnol."},{"key":"7410_CR49","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"7410_CR50","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"7410_CR51","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1021\/acs.jproteome.8b00217","volume":"17","author":"J Navarrete-Perea","year":"2018","unstructured":"Navarrete-Perea, J., Yu, Q., Gygi, S. P. & Paulo, J. A. Streamlined tandem mass tag (SL-TMT) protocol: an efficient strategy for quantitative (phospho)proteome profiling using tandem mass tag-synchronous precursor selection-MS3. J. Proteome Res. 17, 2226\u20132236 (2018).","journal-title":"J. Proteome Res."},{"key":"7410_CR52","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1021\/ac026117i","volume":"75","author":"J Rappsilber","year":"2003","unstructured":"Rappsilber, J., Ishihama, Y. & Mann, M. Stop and go extraction tips for matrix-assisted laser desorption\/ionization, nanoelectrospray, and LC\/MS sample pretreatment in proteomics. Anal. Chem. 75, 663\u2013670 (2003).","journal-title":"Anal. Chem."},{"key":"7410_CR53","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1021\/acs.analchem.8b05399","volume":"91","author":"DK Schweppe","year":"2019","unstructured":"Schweppe, D. K. et al. Characterization and optimization of multiplexed quantitative analyses using high-field asymmetric-waveform ion mobility mass spectrometry. Anal. Chem. 91, 4010\u20134016 (2019).","journal-title":"Anal. Chem."},{"key":"7410_CR54","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1021\/acs.jproteome.9b00759","volume":"19","author":"DK Schweppe","year":"2020","unstructured":"Schweppe, D. K., Rusin, S. F., Gygi, S. P. & Paulo, J. A. Optimized workflow for multiplexed phosphorylation analysis of TMT-labeled peptides using high-field asymmetric waveform ion mobility spectrometry. J. Proteome Res. 19, 554\u2013560 (2020).","journal-title":"J. Proteome Res."},{"key":"7410_CR55","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/pmic.201200439","volume":"13","author":"JK Eng","year":"2013","unstructured":"Eng, J. K., Jahan, T. A. & Hoopmann, M. R. Comet: an open-source MS\/MS sequence database search tool. Proteomics 13, 22\u201324 (2013).","journal-title":"Proteomics"},{"key":"7410_CR56","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nmeth1019","volume":"4","author":"JE Elias","year":"2007","unstructured":"Elias, J. E. & Gygi, S. P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat. Methods 4, 207\u2013214 (2007).","journal-title":"Nat. Methods"},{"key":"7410_CR57","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/978-1-60761-444-9_5","volume":"604","author":"JE Elias","year":"2010","unstructured":"Elias, J. E. & Gygi, S. P. Target-decoy search strategy for mass spectrometry-based proteomics. Methods Mol. Biol. 604, 55\u201371 (2010).","journal-title":"Methods Mol. Biol."},{"key":"7410_CR58","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.cell.2010.12.001","volume":"143","author":"EL Huttlin","year":"2010","unstructured":"Huttlin, E. L. et al. A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174\u20131189 (2010).","journal-title":"Cell"},{"key":"7410_CR59","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/nbt1240","volume":"24","author":"SA Beausoleil","year":"2006","unstructured":"Beausoleil, S. A., Villen, J., Gerber, S. A., Rush, J. & Gygi, S. P. A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat. Biotechnol. 24, 1285\u20131292 (2006).","journal-title":"Nat. Biotechnol."},{"key":"7410_CR60","doi-asserted-by":"publisher","first-page":"D447","DOI":"10.1093\/nar\/gkv1145","volume":"44","author":"JA Vizcaino","year":"2016","unstructured":"Vizcaino, J. A. et al. 2016 Update of the PRIDE database and its related tools. Nucleic Acids Res. 44, D447\u2013D456 (2016).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-07410-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-07410-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-07410-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T16:04:58Z","timestamp":1721318698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-07410-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":60,"journal-issue":{"issue":"8015","published-print":{"date-parts":[[2024,6,6]]}},"alternative-id":["7410"],"URL":"https:\/\/doi.org\/10.1038\/s41586-024-07410-3","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,8]]},"assertion":[{"value":"2 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.G. received research funding from iOnctura and ADC Therapeutics. H.W.L. received research funding from Novartis. A.A.L. received research funding from AbbVie and Stemline Therapeutics; consulting fees from Cimeio Therapeutics, IDRx, Jnana Therapeutics, ProteinQure and Qiagen; and has equity as an advisor for Medzown. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}